Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNT2001
- Development stage
- Unknown
- Lead developer
- POINT Biopharma
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
PNT2001 is a next-generation, small-molecule radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), developed by Scintomics and licensed to Point Biopharma (now a subsidiary of Eli Lilly). Designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC), PNT2001 utilizes a high-affinity ligand that can be labeled with either the beta-emitter Lutetium-177 (177Lu) or the alpha-emitter Actinium-225 (225Ac). This theranostic-ready molecule is engineered to provide superior tumor-to-background ratios compared to first-generation PSMA-targeted agents, potentially improving efficacy while reducing toxicity to healthy tissues such as the salivary glands and kidneys. The program is currently in late-stage clinical development for prostate cancer, representing a follow-on or optimized alternative to earlier PSMA-targeted radioligands.
- Other names
- 177Lu-PNT2001225Ac-PNT2001Lu-177-PNT2001Lu177-PNT2001Lu 177-PNT2001Ac-225-PNT2001Ac225-PNT2001Ac 225-PNT2001
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PNT2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNT2001.